Literature DB >> 3180640

Inheritance of poor phenytoin parahydroxylation capacity in a Dutch family.

P Vermeij1, M D Ferrari, O J Buruma, H Veenema, F A de Wolff.   

Abstract

The mode of inheritance of insufficient phenytoin p-hydroxylation was studied in the family of a patient who had previously suffered from a phenytoin intoxication caused by insufficient metabolism of this drug. This family was compared with a control group. The rate of phenytoin metabolism was derived from the phenytoin/metabolite ratio in serum 6 hours after an oral test dose of 300 mg phenytoin. The propositus, a brother and a sister, were very slow metabolizers of phenytoin, with a metabolic ratio of approximately 20. In the other individuals, 22 family members of the second generation and 37 control subjects, a metabolic ratio of 4.7 +/- 2.2 (mean +/- SD; n = 59) was found. When comparing the members of the second generation (F2) with the control group, two statistically significantly different groups appear to exist: F2, with a metabolic ratio of 6.6 +/- 1.7 (mean +/- SD; n = 22), and the control group, with a metabolic ratio of 3.7 +/- 1.8 (mean +/- SD; n = 37) (p less than 0.001). Based on these results the mode of inheritance of this defect seems to be autosomal recessive.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3180640     DOI: 10.1038/clpt.1988.198

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  5 in total

1.  Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes.

Authors:  C J Doecke; M E Veronese; S M Pond; J O Miners; D J Birkett; L N Sansom; M E McManus
Journal:  Br J Clin Pharmacol       Date:  1991-02       Impact factor: 4.335

2.  Lack of pharmacokinetic interaction between nifedipine, sparteine and phenytoin in man.

Authors:  J H Schellens; P A Soons; J H van der Wart; J W Hoevers; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1991-02       Impact factor: 4.335

Review 3.  PharmGKB summary: phenytoin pathway.

Authors:  Caroline F Thorn; Michelle Whirl-Carrillo; J Steven Leeder; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2012-06       Impact factor: 2.089

Review 4.  Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.

Authors:  J O Miners; D J Birkett
Journal:  Br J Clin Pharmacol       Date:  1998-06       Impact factor: 4.335

Review 5.  Pharmacogenetics: the therapeutic drug monitoring of the future?

Authors:  M H Ensom; T K Chang; P Patel
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 5.577

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.